Methyl 4-aza-5alpha-androsta-3-one-17beta-carboxylate isn’t just a scientific mouthful, it’s the product of decades of hard work in the field of steroid chemistry. Back in the 1960s and 1970s, chemists started hunting for androgen inhibitors to help manage conditions linked to excess hormone activity. That era saw a surge in research around finasteride and dutasteride analogs. This molecule grew out of that push, as scientists experimented with aza modifications to tweak the steroid backbone. By shifting a nitrogen atom into the ring and tinkering with other groups—like that 17beta-carboxylate—researchers noticed new biological effects. Old patents and research reports show the lineage and the steady crawl toward better enzyme inhibition and improved oral bioavailability. In short: it’s the result of people testing, failing, adjusting, and then finally hitting that sweet spot of useful biological activity.
This compound falls under the synthetic steroid class and lands right at the intersection of pharmaceutical research and industrial chemistry. It shows promise for inhibiting 5-alpha-reductase, which makes it a candidate for investigating ways to control hormone-driven conditions. Laboratories working in hormone modulation look at this sort of compound as a tool for everything from prostate disorder studies to hair loss research. In my experience reading scientific journals and talking with uptight chemists at conferences, it’s always these carefully-designed “aza” steroids that spark both debate and excitement—simply because nature didn’t make them, but we saw fit to try.
The pure form of methyl 4-aza-5alpha-androsta-3-one-17beta-carboxylate manifests as a white crystalline powder with respectable stability under standard lab conditions. Its melting point hovers around 170–175°C, giving a clear signal when purity isn’t up to scratch. Solubility can be tricky; organic solvents like chloroform or dimethyl sulfoxide take it up far more easily than water. The molecule brings a moderate molecular weight, about 330–350 g/mol, and holds a moderate to strong log P, nudging it into the range of preferred partitioning for oral bioavailability. The carboxylate handles derivatization chemistry surprisingly well—something not all steroid analogs pull off. Standard analytical methods like HPLC and NMR tell the story of its purity and open the door for high-precision dosing in in-vitro or in-vivo experiments.
Labs and manufacturers lay out clear labels for methyl 4-aza-5alpha-androsta-3-one-17beta-carboxylate, focusing on purity percentages, specific batch numbers, and expiration dates. Material Safety Data Sheets (MSDS) flag any major hazards, which keeps both researchers and lab techs safe. Specifications often include identification by IR and NMR, alongside chromatographic retention times. The actual container needs proper hazard labeling under GHS standards—think red diamonds, black exclamation marks, and a clear notice about storage needs. Without these clear labels and specs, mistakes in experimental research balloon quickly in scale and cost.
Synthesis begins with a base steroid nucleus, most commonly androstane. Chemists introduce the nitrogen ring through a multi-step process involving selective reduction, protection, and functional group transformation. The methyl ester shows up through esterification at the C17 carboxylic acid stage. Steps call for selective catalysts and tight temperature control to dodge side reactions, and the entire process rides on solid purification strategies. Chromatographic separation sifts the product away from unreacted starting material and unwanted byproducts. The process deserves respect—not for being headline-grabbing, but for requiring patience, precision, and a willingness to repeat purification until the grade hits the mark.
In my experience, most chemists tinker with the molecule post-synthesis, looking for new bioactive shapes. Reductive amination swaps out side chains for fresh analogues, while hydrolysis can break down the methyl ester to unveil the parent acid group for alternative biological testing. Standard oxidations help ready the molecule for further coupling or transformation. Functionalizing the core opens up a lot of possibilities for derivative compounds, and the reactions tend to run under mild conditions thanks to the stability of the aza ring and steroid scaffold. This blend of stability and modifiability keeps it in demand across research circles chasing new therapeutic leads.
Anyone who has spent hours combing through chemical catalogs or PubChem knows this molecule accumulates alternate names fast. Synonyms might include “4-aza-17beta-carboxy-5alpha-androstan-3-one methyl ester,” “methyl 4-aza-steroid-17-carboxylate,” and even “methyl finasteride analog.” Commercial names, when available, lean on those modifications—adding “aza” or “methyl ester” to make it clear to buyers and regulators. Some research labs shorthand it as “MAA-17C” or similar, just to ease lab book writing. Knowing the full list of names can mean the difference between success and hours wasted on a misfiled product shipment.
Working with methyl 4-aza-5alpha-androsta-3-one-17beta-carboxylate means gloves, goggles, and closed systems. Inhalation and skin contact risks show up in animal studies, and storage follows similar rules for hazardous lab chemicals. It stays in sealed containers, locked away from moisture and strong acids or bases, and everyone in the lab must sign off on safety training. Waste goes into specialized containers, scheduled for proper chemical disposal every week. Institutional biosafety committees call for regular reviews, and it’s rare to find a modern lab cutting corners on these substances—outside of regulatory fines, the safety risk isn’t worth it.
This molecule’s main spotlight shines in research chasing better treatments for prostate conditions and androgenic disorders. By blocking 5-alpha-reductase, it sidesteps the testosterone-to-dihydrotestosterone pathway, deflecting the triggers for a cluster of hormone-linked health issues. Pharmaceutical teams weigh its oral activity, metabolic fate, and side effect profile as they design preclinical studies. It may also attract the attention of hair loss researchers and dermatology groups, given the links between androgens and sebaceous gland activity. Academic labs with funding and patience look to this compound as a model system for enzyme inhibition studies, mapping structure-activity relationships that drive future breakthroughs.
Researchers from big pharmaceutical companies and universities test methyl 4-aza-5alpha-androsta-3-one-17beta-carboxylate as a lead inhibitor, measuring both its primary enzyme-blocking action and the way the body breaks it down. Investment focuses on improving selectivity, dropping off-target effects, and extending the molecule’s lifespan in the human system. Journals now and then publish cutting-edge studies using this molecule to probe prostate cell lines, animal test models, and even in-silico docking screens to optimize analogs. My own interactions with drug development teams hint at a quiet optimism—progress isn’t always splashy, but the steady gains in understanding mechanism and improving molecular design pay off in the long run.
Toxicologists dive deep before moving a compound toward anything resembling a Phase 1 clinical trial. Here, studies in rodents often highlight liver and kidney as organs at risk, especially under chronic dosing. No compound with steroid roots dodges metabolic scrutiny; scientists track changes in blood counts, hormone levels, and tissue histology for hints of mutagenicity or carcinogenicity. So far, methyl 4-aza-5alpha-androsta-3-one-17beta-carboxylate fares better than early-generation inhibitors—a real win for designers focused on structure over brute force biochemistry. Yet, the need for rigorous screening and careful reporting never fades, knowing a single red flag in toxicology can end years of investment.
The road ahead for methyl 4-aza-5alpha-androsta-3-one-17beta-carboxylate runs through collaboration between biochemists, clinicians, and data scientists. Personalized medicine keeps knocking at the door, pushing for compounds that match patient genotype with therapeutic outcome. If next-generation analogs offer improved metabolic profiles and fewer side effects, this core chemistry could feed into everything from cardiovascular drugs to novel dermatological agents. Advances in AI-assisted design and high-throughput screening promise to speed up discovery and reduce cost. The hope is that future reports bring not only new derivatives but also a deeper understanding of enzyme-driven pathways in human health, mining this chemistry for broader impact.
Methyl 4-aza-5alpha-androsta-3-one-17beta-carboxylate has a name that can make anyone pause. Beneath the long-winded chemistry jargon, this molecule holds a spot in medical research, especially thanks to its backbone, which resembles structures found in several hormones. If you take a look at efforts to develop medicines that target hormone pathways, this compound tends to pop up in the conversation, particularly in prostate health and certain hair-loss therapies.
Researchers look at molecules like this one because of what they can do to enzyme activity, particularly 5-alpha reductase. The enzyme is known to convert testosterone into dihydrotestosterone (DHT). DHT has a hand in some common health issues, including benign prostatic hyperplasia and androgenetic alopecia, or male-pattern balding. By targeting 5-alpha reductase, scientists believe they can slow down, halt, or even reverse some of the unwanted effects tied to excess DHT.
For plenty of guys, DHT is not exactly a villain, but unchecked levels can set off hair loss or prostate growth. Inhibitors derived from molecules like this one lend hope where people want treated—especially those wanting alternatives to medications such as finasteride or dutasteride, the current go-tos. A report from the Journal of Clinical Investigation points out that DHT suppression leads to real, measurable results for hair regrowth and lower urinary tract symptoms. These facts helped shape regulatory decisions and prescriptions in urology for decades now.
I’ve spent time alongside pharmacologists in university labs. Researchers don’t just look for a magic bullet; they check, double-check, and triple-check the safety of everything. Side effects matter just as much as success rates. Getting a compound like methyl 4-aza-5alpha-androsta-3-one-17beta-carboxylate to work safely in people means years of trials. Early promise in the lab does not always survive real-world testing—molecules can break down unpredictably, and even a small chemical change brings unforeseen results.
Some companies take what’s promising about molecules like this and tweak them. One tweak might adjust absorption or reduce risk in people with pre-existing conditions. Here’s where facts matter: Not every version makes it to market, and that sort of transparency keeps both patients and scientists honest.
Many folks ask what the future holds for these kinds of molecules. Researchers see value in designing safer inhibitors—ones that work at lower doses, cause fewer side effects, and offer better quality of life. For example, minimizing the drop in libido or lessening the risk of depression, which some users of older inhibitors have faced. Peer-reviewed studies from Endocrinology point to structure-activity relationship work, where tweaking certain atoms in a molecule brings huge differences in effectiveness and safety.
Pushing forward means involving multiple viewpoints—chemists, doctors, patients, and regulatory agencies all have a voice. The more open the process, the fewer surprises later on. Personally, I believe patient education sits at the core; too many people start therapies without a clear picture of benefits and risks. Conversations between doctors and patients ought to be frank, with the science laid out clearly, warts and all. That’s how trust grows, and how better therapies rise from the lab bench to the prescription pad.
Behind the long chemical name, Methyl 4-Aza-5Alpha-Androsta-3-One-17Beta-Carboxylate lands among the newer synthetic compounds with ties to the world of performance enhancement. It shows up in supplements designed to boost muscle mass or support athletic performance. The compound relates to selective androgen receptor modulators (SARMs) — synthetic options that latch onto testosterone receptors in muscle and bone tissue. Some companies market these with big claims and not much transparency.
Diving through studies, I found little credible, peer-reviewed research on this compound. It does not show up in FDA-approved drug lists. Most sources come from supplement brands or message boards, and their reliability looks shaky at best. Without published human trials, users take real risks every time they swallow one of these pills. This reminds me of the old days at the health food store, where people shared supplements over the counter, trusting a few testimonials over real science.
Synthetic hormones and hormone modulators cause all sorts of side effects. Methyl 4-Aza-5Alpha-Androsta-3-One-17Beta-Carboxylate falls into the same area as other unregulated anabolic agents. Reports from users point to headaches, changes in mood, acne, and trouble with sleep. Blood pressure often rises. Some users developed signs of liver stress, including pain in the upper abdomen, yellowing of the eyes, and fatigue. There’s no way to measure risk properly with such limited real-world data, and that should worry anyone thinking about trying it.
Athletes always chase an edge, but shortcuts like this often do more harm than good. Oral hormones can affect cholesterol, wreck the liver, and even push natural testosterone down, leading to body changes you did not bargain for. I have seen folks lose hair, break out, and fight long-term issues just trying to gain a few extra pounds of muscle. Some ended up needing medical help to balance their hormones after stopping use.
Supplements containing this kind of compound often break anti-doping rules. Agencies like WADA ban related substances, and positive tests can follow users around for years. As for law enforcement, many countries treat new synthetic steroids and SARMs under strict regulations. Products promising quick muscle frequently land vendors and buyers in legal hot water. Just because something ends up online or on a store shelf, that doesn’t mean it’s safe, legal, or worth the gamble.
Trust should rest with licensed doctors and products that clear the hurdles of regulated medicine. Athletes needing support should lean on things like balanced diets, recovery, smart training, and — if needed — medically supervised options. Supplements with a proven safety record and real science behind them have their place, but compounds like Methyl 4-Aza-5Alpha-Androsta-3-One-17Beta-Carboxylate offer more risk than reward.
The promise of instant muscle or endless stamina is an old tune. I keep learning that true performance comes from patience, steady work, and attention to health. The less trust placed in chemical shortcuts, the better life turns out. Looking after ourselves works best when we choose safety and honesty over risky quick fixes.
People in the bodybuilding world and research circles sometimes talk about Methyl 4-Aza-5Alpha-Androsta-3-One-17Beta-Carboxylate like it’s a cheat code. As a synthetic compound tied to steroid research, folks often hope it delivers muscle growth or fat-burning results without all the baggage. Dreams of a shortcut always carry consequences, and if someone takes shortcuts with something this potent, complications can hit hard. Let’s step out of the haze and talk straight: messing with hormones rewires some of the most sensitive circuits in the body.
Younger lifters sometimes shrug off warnings from the older gym crowd or brush past the fine print in supplement shop pamphlets. That’s a mistake. Putting this compound into the mix ramps up the risk for classic androgenic side effects. I’ve seen people end up with acne that sidetracks social lives and leaves scars. Expect hair loss too, especially in folks with a family history of male pattern baldness; those genes don’t play nice with synthetic androgens.
Liver stress shows up more than anyone likes to admit. Methylation gives this compound its potency, but that same chemical tweak strains the liver’s ability to filter toxins. Blood markers like ALT and AST usually jump up, and some people experience jaundice or other signs of liver distress. No quick fix can undo that kind of damage, and doctors see these cases with a heavy heart.
Hormone suppression is real. Taking an androgen analog throws off natural testosterone levels. Some people think cycling off helps the body balance out, but recovery isn’t guaranteed. Testosterone suppression leaves people dealing with low energy, depression, loss of sex drive, and muscle pain. In some cases, the body slows its own testosterone production for weeks or even months, opening the door to longer health issues.
Blood pressure spikes should make anyone pay attention. Endocrine disruptions from these types of chemicals often make the body hold onto sodium, which pushes up blood pressure over time. This brings heart strain and, for some, headaches or even nosebleeds. Ignoring that kind of signal carries risks no amount of gym glory can cover.
Women sometimes get exposed, either through direct use or accidental contact. Deepened voice, clitoral changes, and irregular periods have landed more than a few people in doctors’ offices. These side effects tend to stick around, long after the compound leaves the system.
It’s easy to find anecdotes from people who “felt fine” taking research compounds, but the stories left out are bigger: heart attacks in the late twenties, liver failure down the road, and blood work that never quite returns to baseline. Medical journals don’t gloss over these effects. In 2022, an endocrinology review flagged methylated androgens as a rising cause of hepatic and hormone complications among young adults. That’s no abstract headline.
Education shines brightest in the real world. Medical practitioners, coaches, and gym buddies with scars or health scares all have voices that matter here. Regular blood work, transparency about the risks, and stopping at the first sign of distress go further than half-baked internet advice. The supplements market moves quickly, but real health—once lost—rarely bounces back so easily. Respecting the body’s own balance beats chasing shortcuts every time. If someone values strength for the long haul, steering away from unregulated “research” and investing in habits that last keeps that dream in reach.
Ask anyone who’s spent time digging into hormone modulation—bodybuilding forums, academic papers, or regulatory guidance—about Methyl 4-Aza-5Alpha-Androsta-3-One-17Beta-Carboxylate, and you’ll hear it referenced as a finasteride analogue. This compound pops up mostly in specialist labs and pharmacological research, not pharmacy shelves. The molecule blocks the conversion of testosterone to DHT, which draws attention from those managing androgenic alopecia or exploring prostate health. Still, outside clinical settings, very little consistent information comes up regarding the safe, effective way to dose it.
Clinical data offer the most trusted information. Research on structurally similar agents, like finasteride and dutasteride, shows dose-dependent action with a clear safety window—posing less risk at lower doses, but unwanted side effects when pushed above recommended levels. Experts define standard finasteride doses in the range of 1 to 5 milligrams daily for adults—with hepatic metabolism and half-life playing key roles. By comparison, Methyl 4-Aza-5Alpha-Androsta-3-One-17Beta-Carboxylate has not picked up robust clinical trials. Any advice handed out without medical supervision usually leans on anecdote and risky guesswork. The absence of regulatory body approval for this molecule in human use sends a strong message: dosing lies mostly in the shadows.
Active ingredients in this class of drugs, delivered orally, face metabolism by the liver. Drug manufacturers formulate some versions for topical use instead, aiming to sidestep hepatic first-pass breakdown. Most anecdotal reports, though, describe use as oral tablets or capsules. This means the dose actually absorbed can vary a lot person to person—body weight, metabolism speed, liver health, and even gut bacteria all play a part.
My own background brings stubborn reminders about self-experimentation. Many drawn to compounds that reach the market through research channels ignore the basics: purity checks, accurate scales, or proper storage. I remember a friend, years back, meticulously dissolving research chemicals, only to discover dose calculations that yielded inconsistent results. That story plays out too often, pushing the importance of real measurement and medical supervision.
One fact remains: acting without medical guidance opens a door to unintended consequences. The scalp and prostate both respond strongly to DHT, but so do broader metabolic pathways. Blocking too much androgen can cause depression, sexual dysfunction, or unwanted weight changes. Nobody benefits from dosing instructions pulled from social media posts or speculative blogs. Regulatory standards—to gain FDA or EMA approval—require formal, phased testing. The same applies to laboratory-grade supplies versus pharmaceutical products. Unverified websites selling “research-only” compounds often skip robust quality checks.
If future research paves the way for accepted use of Methyl 4-Aza-5Alpha-Androsta-3-One-17Beta-Carboxylate, published clinical trials will spell out starting doses, blood monitoring, and long-term effects. Until then, the logical path follows real science. Doctors and pharmacists hold critical know-how, able to interpret hormone panels, liver function tests, and risk factors. No shortcut compares to a prescription based on published evidence. Countless horror stories about unregulated use—and my own time spent working alongside clinical researchers—prove that skipping this step causes more headache than progress.
Methyl 4-Aza-5Alpha-Androsta-3-One-17Beta-Carboxylate remains an experimental substance. Anyone asking about dosing faces significant unknowns. Direct advice from a qualified healthcare provider, combined with awareness of supported alternatives, always outweighs the dangers of DIY chemistry.
The name Methyl 4-Aza-5Alpha-Androsta-3-One-17Beta-Carboxylate may not ring familiar for most folks, but this compound pops up often in discussions about muscle growth and body enhancement. Some know it as a designer steroid. Some know it through supplement bottles sold under vague labels. Many want to know – can you pick this up at the pharmacy or health store, or do you need a doctor's green light?
Talking about laws in the US, anabolic steroids and their relatives exist under the Controlled Substances Act. The FDA regulates compounds like testosterone, nandrolone, and their close cousins. As years go on, new synthetic or modified molecules appear. Most are called "designer steroids" and try to sneak around banned lists. Methyl 4-Aza-5Alpha-Androsta-3-One-17Beta-Carboxylate fits that trend, putting it in gray territory.
Some retailers, especially those online and operating overseas, try to sell this without checks. But the DEA and FDA routinely catch up. Compounds like this usually end up on restricted lists. Today, any steroid-like molecule carrying potential for muscle gain, hormonal impact, or abuse faces tough scrutiny. The government updates laws regularly to sweep up new variants. Typical pharmacies won’t sell this compound without a prescription—if they stock it at all.
Prescription rules aren't there to make life harder; they try to keep people safe from the fallout of misuse. Designer steroids come with nasty baggage—liver damage, blood pressure spikes, hormone crashes later, behavioral swings, and risk of long-term endocrine problems. The human body doesn't magically filter out risk with new molecules. Years in fitness and medicine show patterns: people see quick results and rush in, but years later, the downsides show up in lab tests, heart scans, or hospital trips.
Doctors see patients wrestling with sleeplessness, aggression, acne that never clears, and anxiety that lingers for years. Friends disappear, careers stall, and bodies don’t always recover. Medical oversight means testing blood, checking side effects, and pulling the plug before things get critical. A prescription blocks off-the-shelf purchases, and some call that inconvenient. But letting anyone grab a powerful hormone-changing drug could mean stacking up hospital bills, not muscles.
My own time spent coaching at gyms and volunteering at clinics taught me that chatting with health care professionals before diving into unregulated compounds saves headaches in the end. Pros screen for red flags and guide people toward safer ways to build muscle, shed fat, or manage aging. Sometimes, an underlying heart condition or family history rips open trouble the user never saw coming.
A prescription forms a layer between experimenters and a compound with possible long-term damage. It separates a supplement from a hazard. Steroids and their analogs attract all ages, from teens to the retired, as shortcuts over hard work and patience. Legal oversight buys time for health education and prevents black market horror stories taking center stage.
A sensible approach looks at the root problem: what leads someone to seek these substances? Many seek quick fixes for self-esteem, performance, or fear of aging. Better answers start with honesty: talk to a doctor, get tests done, and set real goals. No supplement, legal or not, replaces hard work backed by science, proper sleep, and clean nutrition. For anyone thinking about Methyl 4-Aza-5Alpha-Androsta-3-One-17Beta-Carboxylate, chatting with a physician, not a supplement salesman, lights a safer path.
| Names | |
| Preferred IUPAC name | Methyl (5R,8R,9S,10R,13S,14S)-4-aza-10,13-dimethyl-3-oxo-1,2,5,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-17-carboxylate |
| Other names |
11-Oxo
Adrenosterone |
| Pronunciation | /ˈmɛθɪl fɔːr ˈeɪzə faɪv ˈælfə ænˈdrɒstə θriː oʊn ˈsɪvənˌtiː ˈbeɪtə kɑːrˈbɒksɪˌleɪt/ |
| Preferred IUPAC name | methyl (1S,2R,10R,11S,14S,15S)-2,15-dimethyl-5-oxo-14,15,16,17-tetrahydro-1H-cyclopenta[a]phenanthridine-17-carboxylate |
| Other names |
11-Oxo
11-OXO Adrenosterone |
| Pronunciation | /ˈmɛθɪl fɔːr ˈæzə faɪvˈæl.fə ænˈdrɒstə θriː oʊn sɪvənˈtiːn ˈbiːtə kɑːrˈbɒksɪ.leɪt/ |
| Identifiers | |
| CAS Number | 979-02-2 |
| Beilstein Reference | 1248706 |
| ChEBI | CHEBI:76273 |
| ChEMBL | CHEMBL259493 |
| ChemSpider | 157327 |
| DrugBank | DB06634 |
| ECHA InfoCard | 100.253.576 |
| Gmelin Reference | 67836 |
| KEGG | C17536 |
| MeSH | D000928 |
| PubChem CID | 164660 |
| RTECS number | KL4025000 |
| UNII | I08O7OMS2H |
| UN number | UN3272 |
| CompTox Dashboard (EPA) | DTXSID4044618 |
| CAS Number | 979-02-2 |
| Beilstein Reference | 2865102 |
| ChEBI | CHEBI:76272 |
| ChEMBL | CHEMBL2103930 |
| ChemSpider | 16217213 |
| DrugBank | DB01536 |
| ECHA InfoCard | ECHA InfoCard: 100042-142-1 |
| Gmelin Reference | 127208 |
| KEGG | C18546 |
| MeSH | D000928 |
| PubChem CID | 10165739 |
| RTECS number | MU2625000 |
| UNII | 5L8I8J6E51 |
| UN number | UN3272 |
| CompTox Dashboard (EPA) | DTXSID7087002 |
| Properties | |
| Chemical formula | C20H29NO3 |
| Molar mass | 327.42 g/mol |
| Appearance | White solid. |
| Odor | Odorless |
| Density | 1.2 g/cm3 |
| Solubility in water | Insoluble |
| log P | 0.97 |
| Vapor pressure | <1.0E-8 hPa at 25 °C |
| Acidity (pKa) | 13.92 |
| Basicity (pKb) | 5.54 |
| Refractive index (nD) | 1.570 |
| Dipole moment | 2.23 D |
| Chemical formula | C20H29NO3 |
| Molar mass | 327.41 g/mol |
| Appearance | White to off-white powder |
| Odor | Odorless |
| Density | 1.2 g/cm3 |
| Solubility in water | Slightly soluble in water |
| log P | 0.8 |
| Acidity (pKa) | 11.59 |
| Basicity (pKb) | 7.74 |
| Refractive index (nD) | 1.556 |
| Dipole moment | 3.12 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 486.6 J·mol⁻¹·K⁻¹ |
| Std molar entropy (S⦵298) | 428.4 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | A14AA05 |
| ATC code | A14AA05 |
| Hazards | |
| Main hazards | Causes skin and eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS02,GHS07 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | P261, P264, P271, P272, P280, P302+P352, P305+P351+P338, P312, P321, P332+P313, P362+P364 |
| Flash point | > 170.7 °C |
| NIOSH | Not Listed |
| PEL (Permissible) | Not established |
| REL (Recommended) | 50 mg |
| Main hazards | Harmful if swallowed, causes serious eye irritation. |
| GHS labelling | GHS02,GHS07 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | H302, H315, H319, H335 |
| Precautionary statements | P261, P264, P271, P272, P273, P280, P302+P352, P305+P351+P338, P308+P313, P332+P313, P362+P364 |
| NFPA 704 (fire diamond) | Health: 2, Flammability: 1, Instability: 0, Special: - |
| Flash point | Flash point: >110°C |
| LD50 (median dose) | LD50: 5000 mg/kg (rat, oral) |
| NIOSH | Not Listed |
| PEL (Permissible) | Not established |
| REL (Recommended) | 20 mg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
4-Aza-5alpha-androstan-17beta-carboxylic acid
Finasteride Dutasteride Methyltestosterone Testosterone Androstanolone Epiandrosterone 17beta-Hydroxy-4-aza-5alpha-androstan-3-one Methyl 4-aza-5alpha-androsta-3,17-dione |